ASKA Pharmaceutical Holdings Co.,Ltd. [4886.T]
TOKYO, May 25 (Pulse News Wire) – Aska Pharmaceutical Holdings CO.,LTD. (4886.T) announced plans to seek shareholder approval for anti-takeover measures during its upcoming annual shareholders' meeting scheduled for June 24, 2026.
The proposal comes amid ongoing concerns over potential large-scale acquisition activities by the Dalton group, which includes Dalton Investments Inc., NIPPON ACTIVE VALUE FUND PLC, and others. In light of recent events, including Dalton's aggressive stock accumulation since late 2024 and multiple failed attempts to comply with the company’s established defense mechanisms, ASKA believes there is a significant risk that the Dalton group could initiate large-scale acquisitions without adhering to agreed procedures. This would likely harm the company's long-term value and shareholder interests.
Additionally, ASKA highlighted the potential negative impact of such actions, citing previous instances where Dalton groups sought management buyouts (MBOs) and leveraged buyout (LBO) loans, leading to financial instability and reduced investment flexibility. Independent directors advised respecting the proposed measures to protect against these risks. The company emphasized that should the Dalton group proceed with unauthorized acquisitions, it could lead to structural oppression of minority shareholders, forcing them to sell their stakes prematurely due to lack of control over key decisions.
Therefore, obtaining shareholder consent beforehand is crucial to ensure fair treatment and maintain corporate stability.
🟢 Confidence: High AI-translated content.